GSK Plc Form 6-K Summary
Business Context and Reporting Period
GSK Plc, a global biopharma company, filed this Form 6-K on March 6, 2026, to announce the submission of its 2025 Annual Report on Form 20-F. The filing covers the fiscal year ended December 31, 2025, and includes audited financial statements.
Key Financial Metrics
The provided text is a cover announcement and does not contain specific financial data. Revenue, profit, cash flow, margins, debt, and liquidity figures are not present in this document; they are contained within the referenced 2025 Annual Report on Form 20-F.
Material Changes
No material changes or comparative financial data are disclosed in this filing text. Investors must refer to the full Annual Report for year-over-year analysis.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties. Specific risk factors are detailed in Item 3.D "Risk factors" of the 2025 Annual Report on Form 20-F. No specific guidance or management commentary on future performance is included in this text.
Key Facts for Investor Verification
- The 2025 Annual Report on Form 20-F is available online at annualreport.gsk.com and www.sec.gov.
- A hard copy of the Annual Report and Notice of Annual General Meeting will be available on or about March 25, 2026.
- Shareholders may request free hard copies of audited financial statements via Computershare Investor Services (UK) or J.P. Morgan Chase Bank, N.A. (US).
- Specific financial results for the year ended December 31, 2025, are not listed in this Form 6-K and must be retrieved from the full Annual Report.